Keeping the heart patient in circulation: Persantin.

Contributors

C.H. Boehringer Ingelheim Limited

Publication/Creation

Sandwich, Kent: C. H. Boehringer Limited, [1962?]

Persistent URL

https://wellcomecollection.org/works/t2jfjgds

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



KEEPING THE HEART PATIENT IN CIRCULATION





Manufactured and distributed in the U.K. by Pfizer Limited Sandwich, Kent, for C. H. BOEHRINGER SOHN, INGELHEIM am RHEIN Registered proprietors of the Trade Mark

*Regd. Trade Mark

12161

INDICATIONS:

Angina pectoris, Myocardial Infarction, Heart failure.

DOSAGE

Angina pectoris: 2 tabs t.d.s. Severe forms may require preliminary

parenteral treatment.

Myocardial infarction: 10 mg. (one ampoule) Persantin I.V. or I.M. as soon as shock has been brought under control. In milder cases this may occur spontaneously or in response to simple measures (rest, warmth, morphine) within 8-12 hours. In cases associated with severe shock sufficient time should be allowed for the appropriate resuscitative measures to take effect before starting treatment. This should be followed by 10 mg. I.V. or I.M. b.d. for seven to ten days, after which oral treatment with 2 tabs. t.d.s. may be instituted. Heart failure: 1 tab. q.d.s.

PACKS & BASIC COST TO N.H.S.
Sugar-coated tablets, each containing 25 mg. of Persantin:
Bottles of 30 9s. 6d
Bottles of 200 £2 17s. 0d. plus 27½ per cent P.T.

Ampoules of 2 ml. each containing 10 mg. of Persantin: Cartons of 5 6s. 6d. Plus $27\frac{1}{2}$ per cent P.T.